How Tirzepatide affects patients with heart failure and heart disease Tirzepatide significantly reduced the risk of cardiovascular death or worsening heart failure events, along with improvements in health-related quality of life, functional capacity, and exercise tolerance
[PubMed] [Google Scholar] 67.Tanaka M., Yoshida T., Okamoto K., Hirai S
GLP-1 drugs suppress appetite, alter taste preferences, and accelerate satiety, according to The Food Institute, and users have reported consuming between 30 percent and 40 percent fewer calories while taking the medications, prioritizing protein and hydration and experiencing less emotional eating
These include: Nausea (the most frequently reported adverse effect) Vomiting Diarrhoea Constipation Decreased appetite (which, while contributing to weight loss, can occasionally be excessive) These effects were generally mild to moderate in severity and occurred most frequently during the dose-escalation phase
Obesity is prevalent across every socioeconomic status in America
